The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 29, 2022

Filed:

Jun. 14, 2018
Applicant:

Erasmus University Medical Center Rotterdam, Rotterdam, NL;

Inventors:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61P 21/00 (2006.01); A61K 31/712 (2006.01); A61K 31/7125 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/712 (2013.01); A61K 31/7125 (2013.01); A61K 48/0058 (2013.01); A61P 21/00 (2018.01); C12N 15/1137 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2320/31 (2013.01); C12N 2320/33 (2013.01); C12Y 302/0102 (2013.01);
Abstract

The invention relates to method for repairing aberrant; splicing, wherein such aberrant: splicing is caused by the presence of a natural pseudo exon, comprising blocking of either the natural cryptic 3' splice site or the natural cryptic 5′ splice site of said natural pseudo exon with an antisense oligomeric compound (AON). Further, the invention comprises an antisense oligomeric compound targeting SEQ ID NO: 1 or SEQ ID NO: 171, preferably selected from the sequences of SEQ ID NO: 267-2040, sequences that are complementary to said sequences or sequences that have an identity of 80% with said sequences or the complementary sequences. The invention further envisages the use of two antisense oligomeric compounds, a first AON targeting SEQ ID NO: 1 and a second targeting AON or SEQ ID NO: 171. These AONs are specifically for use in the treatment of Pompe disease. It is an aspect of the invention that antisense therapy using the above AONs or combinations thereof is used in combination with ERT.


Find Patent Forward Citations

Loading…